Revolution Medicines (RVMD) EBIT (2019 - 2026)

Revolution Medicines' EBIT history runs 8 years deep, the most recent figure standing at -$445.2 million for Q1 2026.

• In Q1 2026, EBIT fell 84.92% year-over-year to -$445.2 million; the TTM figure through Mar 2026 stood at -$442.0 million (up 44.01% YoY), while the FY2025 annual figure was -$237.6 million, up 65.55% from the prior year.
• EBIT was -$445.2 million for Q1 2026 at Revolution Medicines, down from $583.2 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $583.2 million in Q4 2025 to a low of -$445.2 million in Q1 2026.
• Historically, EBIT has averaged -$124.6 million across 5 years, with a median of -$140.9 million in 2024.
• The sharpest annual moves came in 2023 and 2025: EBIT plunged 191.67% in 2023, then soared 369.6% in 2025.
• A 5-year view of EBIT shows it stood at -$61.7 million in 2022, then slumped by 191.67% to -$180.0 million in 2023, then dropped by 20.18% to -$216.3 million in 2024, then jumped by 369.6% to $583.2 million in 2025, then slumped by 176.35% to -$445.2 million in 2026.
• The last three EBIT figures came in at -$445.2 million (Q1 2026), $583.2 million (Q4 2025), and -$315.3 million (Q3 2025), per Business Quant data.